Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 20/20 | 0.74 |
| ▸ | PPARG | P37231 | 16/20 | 0.74 |
| ▸ | PPARD | Q03181 | 16/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482416 | 1.00 | PPARA (0.74) | PPARAPPARGPPARD | |
| SCHEMBL6482412 | 1.00 | PPARA (0.74) | PPARAPPARGPPARD | |
| SCHEMBL6497025 | 1.00 | PPARA (0.74) | PPARAPPARGPPARD | |
| SCHEMBL5634053 | 0.92 | PPARA (0.85) | PPARAPPARGPPARD | |
| SCHEMBL5634051 | 0.92 | PPARA (0.85) | PPARAPPARGPPARD | |
| SCHEMBL14544678 | 0.91 | PPARA (0.78) | PPARAPPARGPPARD | |
| SCHEMBL14544579 | 0.91 | PPARA (0.78) | PPARAPPARGPPARD | |
| SCHEMBL6497250 | 0.89 | PPARA (0.87) | PPARAPPARGPPARD | |
| SCHEMBL6482291 | 0.89 | PPARA (0.87) | PPARAPPARGPPARD | |
| SCHEMBL6482286 | 0.89 | PPARA (0.87) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030195200-A1 | Compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-10-16 | — | — | US | claimed |
| US-6555577-B1 | For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | claimed |
| US-6900224-B2 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-6867218-B2 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-03-15 | — | — | US | disclosed |
| US-20040038975-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY | 2004-02-26 | — | — | US | disclosed |
| US-20030195200-A1 | Compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-10-16 | — | — | US | disclosed |
| US-6555577-B1 | For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038975-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, NQO2, Q6ZSR9 | PPARA 1531/4885PPARG 2048/4885PPARD 1214/4885 |
| US-20030195200-A1 | Compounds, their preparation and use | PPARG, PPARA, PPARD | PPARA 2/4885PPARG 1/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.